Revenue
$65.18B
Fiscal year ended 2025-12-31Operating income
Unavailable
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31ELI LILLY & Co (LLY) reported revenue of $65.18B and net income of $20.64B for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ELI LILLY & Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B |
| Gross profit | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $15.51B |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.10M | $2.74B |
| Research & development | Unavailable | Unavailable | Unavailable | $7.19B | $6.93B | $5.98B | $5.60B | $5.05B | $5.10B | $5.31B |
| Weighted-average diluted shares | shares 899.30M | shares 904.10M | shares 903.30M | shares 904.62M | shares 911.68M | shares 912.50M | shares 935.68M | shares 1.03B | shares 1.05B | shares 1.06B |
| Pretax income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.30B | $3.37B |
| Income tax expense | $5.09B | $2.09B | $1.31B | $561.60M | $573.80M | $1.04B | $628.00M | $529.50M | $2.39B | $636.40M |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 |
| Selling, general & administrative | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $5.98B | $6.53B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B | $2.34B | $7.32B | $6.54B | $4.58B |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B |
| Current assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B | $13.71B | $20.55B | $19.20B | $15.10B |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B | $12.48B | $11.78B | $11.89B | $14.54B | $10.99B |
| Total equity incl. NCI | $26.54B | $14.27B | $10.86B | $10.78B | $9.15B | $5.83B | $2.70B | $10.91B | $11.67B | $14.08B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B | $3.98B | $3.19B | $3.10B | $4.46B | $3.56B |
| Accounts receivable | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B | $5.88B | $4.55B | $4.59B | $4.55B | $4.03B |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B | $3.77B | $3.68B | $1.37B | $4.37B | $3.97B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B | $16.59B | $13.82B | $9.20B | $9.94B | $8.37B |
| Accounts payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B | $1.61B | $1.41B | $1.21B | $1.41B | $1.35B |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B | $5.62B | $4.85B |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -$2.87B | -$2.26B | -$8.08B | $1.91B | -$3.78B | -$3.14B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B | -$3.14B | -$2.32B | -$5.90B | $142.60M | -$559.80M |
| Net change in cash | $4.00B | $449.00M | $752.00M | -$1.75B | $161.40M | $1.32B | -$5.66B | $1.46B | $1.95B | $915.70M |
| Stock-based compensation | $626.00M | $646.00M | $629.00M | $371.10M | $342.80M | $308.10M | $312.40M | $279.50M | $281.30M | $255.30M |
| Common dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B |
| Common share repurchases | $4.11B | $2.50B | $750.00M | $1.50B | $1.25B | $500.00M | $4.40B | $4.15B | $299.80M | $600.10M |
| Depreciation & amortization | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.0% | 1.4% | 1.8% | 1.3% | 1.2% | 1.3% | 1.4% | 1.3% | 1.4% | 1.2% |
| Current ratio | 1.58x | 1.15x | 0.94x | 1.05x | 1.23x | 1.40x | 1.16x | 1.73x | 1.32x | 1.37x |
| Revenue YoY growth | 44.7% | 32.0% | 19.6% | 0.8% | 15.4% | 9.9% | 3.8% | 7.6% | -5.9% | Unavailable |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 24.4% | 25.1% | 23.5% | 25.5% | 25.0% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | 1.54x | 2.00x | 1.69x | 1.37x | 1.68x | 2.85x | 5.12x | 0.84x | 0.85x | 0.59x |
| Effective tax rate | 19.8% | 16.5% | 20.0% | 8.3% | 9.3% | 14.3% | 11.9% | 14.4% | 103.7% | 18.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LLY in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.